Advertisement

Medical Management 3: Biologicals

  • Sofie Coenen
  • Ellen Weyts
  • Patricia Geens
  • Marc FerranteEmail author
Chapter

Abstract

Anti-tumour necrosis factor (anti-TNF) agents have led to major progress for IBD patients refractory to conventional treatment (corticosteroids and immunosuppressive therapy). Infliximab and adalimumab have proven their efficacy for inducing and maintaining remission in CD and UC, and infliximab is also effective for acute severe colitis and perianal fistulising Crohn’s disease. For both diseases a third anti-TNF agent has demonstrated its efficacy in a randomized controlled trial. Golimumab is available for UC patients and certolizumab pegol for CD patients, but the latter only in Switzerland and Northern America.

However, managing IBD remains challenging as prognosis and outcome vary between patients. Moreover, one-third of IBD patients seem to be primary non-responders, and an additional 40% loses effect over time (secondary nonresponders).

References

  1. Ben-Horin S, Chowers Y (2011) Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 33:987–995CrossRefGoogle Scholar
  2. Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285CrossRefGoogle Scholar
  3. Brandse JF, van den Brink GR, Wildenberg ME et al (2015) Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 149:350–355.e2CrossRefGoogle Scholar
  4. Breynaert C, Ferrante M, Fidder H et al (2011) Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 106:778–785CrossRefGoogle Scholar
  5. Colombel JF, Sandborn WJ, Rutgeerts P et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65CrossRefGoogle Scholar
  6. Colombel JF, Rutgeerts PJ, Sandborn WJ et al (2014) Adalimumab induces deep remission in patients with Crohn’s disease. Clin Gastroenterol Hepatol 12(3):414–22.e5CrossRefGoogle Scholar
  7. Ferrante M, Vermeire S, Rutgeerts PJ (2014) Drug safety evaluation of certolizumab pegol. Expert Opin Drug Saf 13:255–266CrossRefGoogle Scholar
  8. Ford AC, Sandborn WJ, Khan KJ et al (2011) Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106:644–659; quiz 660CrossRefGoogle Scholar
  9. Gibson DJ, Heetun ZS, Redmond CE et al (2015) An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 13:330–335CrossRefGoogle Scholar
  10. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549CrossRefGoogle Scholar
  11. Hanauer SB, Sandborn WJ, Rutgeerts P et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the classic-I trial. Gastroenterology 130:323–332CrossRefGoogle Scholar
  12. Ho GT, Mowat A, Potts L et al (2009) Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 29:527–534CrossRefGoogle Scholar
  13. Jarnerot G, Hertervig E, Friis-Liby I et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811CrossRefGoogle Scholar
  14. Jørgensen KK, Olsen IC, Goll GL et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389:2304–2316CrossRefGoogle Scholar
  15. Kim YH, Ye BD, Pesegova M et al (2017) DOP061 phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: early efficacy and safety results. J Crohn’s Colitis 11:S62CrossRefGoogle Scholar
  16. Laharie D, Bourreille A, Branche J et al (2015) Long-term outcomes in a cohort of patients with acute severe ulcerative colitis refractory to intravenous steroids treated with cyclosporine or infliximab. J Crohn’s Colitis 9:S10–S11CrossRefGoogle Scholar
  17. Lichtenstein GR, Feagan BG, Cohen RD et al (2012) Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREATTM registry. Am J Gastroenterol 107:1409–1422CrossRefGoogle Scholar
  18. Long MD, Herfarth HH, Pipkin C et al (2010) Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 8:268–274CrossRefGoogle Scholar
  19. Pariente B, Laharie D (2014) Review article: Why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 40:338–353CrossRefGoogle Scholar
  20. Peyrin-Biroulet L, Lémann M (2011) Review article: Remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 33:870–879CrossRefGoogle Scholar
  21. Peyrin-Biroulet L, Reinisch W, Colombel J-F et al (2014) Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 63:88–95CrossRefGoogle Scholar
  22. Rahier JF, Magro F, Abreu C et al (2014) Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8:443–468CrossRefGoogle Scholar
  23. Reinisch W, Sandborn WJ, Hommes DW et al (2011) Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60:780–787CrossRefGoogle Scholar
  24. Russo EA, Iacucci M, Lindsay JO et al (2010) Survey on the use of adalimumab as maintenance therapy in Crohn’s disease in England and Ireland. Eur J Gastroenterol Hepatol 22:334–339CrossRefGoogle Scholar
  25. Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476CrossRefGoogle Scholar
  26. Sandborn W (2013) Adalimumab in the treatment of moderate-to-severe ulcerative colitis: ULTRA 2 trial results. Gastroenterol Hepatol 9:317–320Google Scholar
  27. Sandborn WJ, Rutgeerts P, Enns R et al (2007a) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146:829–838CrossRefGoogle Scholar
  28. Sandborn WJ, Feagan BG, Stoinov S et al (2007b) Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 357:228–238CrossRefGoogle Scholar
  29. Sandborn WJ, Van Assche G, Reinisch W et al (2012) Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2):257–65.e1CrossRefGoogle Scholar
  30. Sandborn WJ, Feagan BG, Marano C et al (2014a) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85–95CrossRefGoogle Scholar
  31. Sandborn WJ, Feagan BG, Marano C et al (2014b) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146(1):96–109.e1CrossRefGoogle Scholar
  32. Sands BE, Blank MA, Patel K et al (2004) Long-term treatment of rectovaginal fistulas in Crohn’s disease: Response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2:912–920CrossRefGoogle Scholar
  33. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al (2007) Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 357:239–250CrossRefGoogle Scholar
  34. Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2):CD008794.  https://doi.org/10.1002/14651858.CD008794.pub2
  35. Swoger JM, Loftus EV, Tremaine WJ et al (2010) Adalimumab for Crohn’s disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis 16:1912–1921CrossRefGoogle Scholar
  36. Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al (2008) Withdrawal of Immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134:1861–1868CrossRefGoogle Scholar
  37. Van Assche G, Vermeire S, Noman M et al (2010) Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. J Crohn’s Colitis 4:329–333CrossRefGoogle Scholar
  38. Vande Casteele N, Ferrante M, Van Assche G et al (2015) Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148:1320–1329.e3CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sofie Coenen
    • 1
  • Ellen Weyts
    • 1
  • Patricia Geens
    • 1
  • Marc Ferrante
    • 1
    Email author
  1. 1.Department of Gastroenterology and HepatologyUniversity Hospitals Leuven, UZ Leuven, Campus GasthuisbergLeuvenBelgium

Personalised recommendations